序号股票简称PE(TTM)PE(静)市净率总市值(元)9奥泰生物17.6018.561.4256.13亿行业平均 53.5248.844.67111.58亿行业中值37.1437.112.5651.72亿1九安医疗10.9411.060.86184.59亿2英科医疗 12.7713.771.14201.84亿3新华医疗15.2014.091.2497.43亿4奥美医疗15.9515.631.6457.63亿5山东药玻 15.9516.001.83150.91亿6振德医疗16.0515.131.0258.27亿7康德莱16.5816.591.3735.73亿8九强生物 17.0215.832.0984.31亿10维力医疗17.8218.532.0940.65亿11三鑫医疗19.1519.163.1543.57亿12安图生物 19.3418.462.48220.51亿 来源：金融界 杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品 是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。2024年9月，公司获 评"杭州市上市企业ESG战略慈善影响力先锋20" ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Aotai Biological, a company in the medical device industry, which has a current market capitalization of 5.304 billion yuan and a rolling PE ratio of 16.63 times, significantly lower than the industry average of 52.06 times [1][2] - Aotai Biological's main business focuses on the research, production, and sales of in vitro rapid diagnostic reagents, with key products including infectious disease tests, drug abuse tests, women's health tests, COVID-19 tests, tumor tests, and myocardial tests [1] - As of March 31, 2025, Aotai Biological had 5,431 shareholders, an increase of 165 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - In the first quarter of 2025, Aotai Biological reported revenue of 208 million yuan, representing a year-on-year increase of 4.28%, and a net profit of 61.2163 million yuan, reflecting a year-on-year growth of 36.68%, with a gross profit margin of 55.63% [2] - The company ranks 39th in terms of PE ratio within its industry, which has a median PE ratio of 37.22 times [1][2] - Aotai Biological has received several accolades, including being named one of the "Top 20 ESG Strategic Philanthropy Influencers" in Hangzhou and recognized as a "2024 A-share Listed Company Growth Power Annual Enterprise" [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aotai Biological Technology Co., Ltd., emphasizing its growth in revenue and net profit, as well as its competitive valuation in the medical device industry [1][2] Group 2 - As of the first quarter of 2025, the company reported a revenue of 208 million yuan, representing a year-on-year increase of 4.28%, and a net profit of 61.22 million yuan, reflecting a year-on-year growth of 36.68% [2] - The company's rolling price-to-earnings (PE) ratio stands at 16.19, significantly lower than the industry average of 49.12 and the industry median of 36.07, indicating a favorable valuation compared to peers [1][2] - Aotai Biological's total market capitalization is 5.164 billion yuan, with 30 institutions holding shares, including 24 funds, 5 other entities, and 1 social security fund, totaling 44.01 million shares valued at 3.224 billion yuan [1]